HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. The company employs 1,796 full-time employees The company went IPO on 2006-05-19. The firm operates its business through two segments. Oncology Immunology segment is engaged in the discovery, development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Among it, research and development (R&D) includes research and development activities covering drug discovery, development, manufacturing and regulatory functions, out-licensing of in-house developed drugs, as well as administrative activities to support research and development operations, marketed products comprises the invoiced sales, marketing, manufacture and distribution of drugs developed from research and development activities. Other Ventures segment is engaged in the other commercial businesses which include the sales, marketing, manufacture and distribution of other prescription drugs and healthcare products.
Financials in millions USD. Fiscal year is February - January.
Breakdown
TTM
12/31/2025
06/30/2025
12/31/2024
06/30/2024
12/31/2023
Revenue
548
270
277
324
305
305
Revenue Growth (YoY)
-13%
-17%
-9%
6%
-43%
36%
Cost of Revenue
336
168
167
168
180
176
Gross Profit
212
102
110
155
125
129
Selling, General & Admin
103
61
41
55
57
64
Research & Development
148
76
71
116
95
157
Operating Expenses
251
137
113
171
153
222
Other Non Operating Income (Expenses)
60
39
21
19
22
14
Pretax Income
521
2
518
16
29
-66
Income Tax Expense
63
0
63
4
2
1
Net Income
456
1
454
11
25
-67
Net Income Growth
1,132%
-91%
1,716%
-115.99%
-85%
-66%
Shares Outstanding (Diluted)
873.21
873.21
872.56
873.12
872.53
852.37
Shares Change (YoY)
0%
0%
0%
2%
1%
1%
EPS (Diluted)
0.52
0
0.52
0.01
0.02
-0.07
EPS Growth
1,112%
-84%
1,661%
-117%
-85%
-66%
Free Cash Flow
-88
3
-92
32
-49
-15
Free Cash Flow Per Share
--
--
--
--
--
--
Gross Margin
38.68%
37.77%
39.71%
47.83%
40.98%
42.29%
Operating Margin
-7.11%
-12.96%
-1.08%
-4.93%
-8.85%
-30.49%
Profit Margin
83.21%
0.37%
163.89%
3.39%
8.19%
-21.96%
Free Cash Flow Margin
-16.05%
1.11%
-33.21%
9.87%
-16.06%
-4.91%
EBITDA
-26
-28
3
-10
-21
-89
EBITDA Margin
-4.74%
-10.37%
1.08%
-3.08%
-6.88%
-29.18%
D&A For EBITDA
13
7
6
6
6
4
EBIT
-39
-35
-3
-16
-27
-93
EBIT Margin
-7.11%
-12.96%
-1.08%
-4.93%
-8.85%
-30.49%
Effective Tax Rate
12.09%
0%
12.16%
25%
6.89%
-1.51%
Follow-Up Questions
What are HUTCHMED (China) Limited's key financial statements?
According to the latest financial statement (Form-10K), HUTCHMED (China) Limited has a total asset of $0, Net loss of $0
What are the key financial ratios for HCM?
HUTCHMED (China) Limited's Current ratio is 0, has a Net margin is 0, sales per share of $0.
How is HUTCHMED (China) Limited's revenue broken down by segment or geography?
HUTCHMED (China) Limited largest revenue segment is Oncology/Immunology - Marketed Products, at a revenue of 2,118,769,307 in the most earnings release.For geography, China is the primary market for HUTCHMED (China) Limited, at a revenue of 3,530,161,153.
Is HUTCHMED (China) Limited profitable?
no, according to the latest financial statements, HUTCHMED (China) Limited has a net loss of $0
Does HUTCHMED (China) Limited have any liabilities?
no, HUTCHMED (China) Limited has liability of 0
How many outstanding shares for HUTCHMED (China) Limited?
HUTCHMED (China) Limited has a total outstanding shares of 0